Oppenheimer & Co’s Impax Laboratories, Inc. IPXL Stock Holding History

Oppenheimer & Co’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-9,900	Closed	-$455K	–	1519
2015 Q2	$455K	Buy	+9,900	New	+$470K	0.01%	926

Other funds holding IPXL

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Oppenheimer & Co's IPXL Position: Q3 2015 in Review

Oppenheimer & Co sold out of Impax Laboratories, Inc. (IPXL) in Q3 2015, closing a stake of 9,900 shares — an estimated $455K sold.

Oppenheimer & Co first reported a position in IPXL in Q2 2015 and held it in 1 quarter. The position peaked at $455K in Q2 2015. 195 funds tracked by Wall St. Rank hold IPXL as of Q3 2015.

Oppenheimer & Co reported no remaining Impax Laboratories, Inc. position as of Q3 2015 after selling out during the quarter.
Oppenheimer & Co sold 9,900 Impax Laboratories, Inc. shares in Q3 2015, an estimated $455K.
Oppenheimer & Co first reported a position in Impax Laboratories, Inc. in Q2 2015 and held it in 1 quarter.
Oppenheimer & Co's Impax Laboratories, Inc. position peaked at $455K in Q2 2015.
195 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2015.

Based on Oppenheimer & Co's 13F filing for Q3 2015, filed 13 Nov 2015.